Pharmacyclics Inc., with partner Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, became the latest in a small handful of companies to gain "breakthrough therapy designation," a new category that could let drug developers win approval of their drug candidates based on single, Phase I trials.